IMPORTANT SAFETY INFORMATIONPRESCRIBING INFORMATION

FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated.

Dose modifications for all other treatment-related toxicities1

Dose omissions and/or reductions may be needed to manage adverse drug reactions

Dose modifications for Grade 3-4 treatment‐related toxicities

*Per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE, Version 3.0)

Reference:

  • Folotyn [package insert]. Westminster, CO: Allos Therapeutics, Inc.